423 related articles for article (PubMed ID: 10361549)
1. The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT
Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549
[TBL] [Abstract][Full Text] [Related]
2. Target to apoptosis: a hopeful weapon for prostate cancer.
Tang DG; Porter AT
Prostate; 1997 Sep; 32(4):284-93. PubMed ID: 9288188
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer.
Kyprianou N
World J Urol; 1994; 12(6):299-303. PubMed ID: 7881465
[TBL] [Abstract][Full Text] [Related]
4. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.
Isaacs JT; Kyprianou N
Urol Res; 1987; 15(3):133-8. PubMed ID: 3307086
[TBL] [Abstract][Full Text] [Related]
5. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
6. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
7. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
8. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
12. Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer; 2000 Jun; 88(12 Suppl):3009-14. PubMed ID: 10898345
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death as a new target for prostatic cancer therapy.
Kyprianou N; Martikainen P; Davis L; English HF; Isaacs JT
Cancer Surv; 1991; 11():265-77. PubMed ID: 1841755
[TBL] [Abstract][Full Text] [Related]
15. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.
Lee EC; Tenniswood MP
J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758
[TBL] [Abstract][Full Text] [Related]
16. Endocrine treatment in prostate cancer.
Denis LJ; Griffiths K
Semin Surg Oncol; 2000; 18(1):52-74. PubMed ID: 10617897
[TBL] [Abstract][Full Text] [Related]
17. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy for prostate cancer: current status and future prospects.
Miyamoto H; Messing EM; Chang C
Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
[TBL] [Abstract][Full Text] [Related]
19. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
